AIDS Treatment News logo      

November 15, 2010

Good Early Results for New ViiV HIV Integrase Inhibitor

POZ: "An experimental integrase inhibitor from ViiV Healthcare, currently known as S/GSK1349572 (S/GSK-572), was as effective as efavirenz (found in Sustiva and Atripla) in controlling HIV levels with fewer side effects over 24 weeks in a Phase II study. These data were presented at the 10th International Congress on Drug Therapy in HIV Infection, which was held November 7 to 11 in Glasgow and reported by the National AIDS Treatment Advocates Project (NATAP).

"Although the current crop of recommended antiretroviral (ARV) drugs is quite potent, each med has its disadvantages. Some have troublesome side effects, while others must be taken several times a day. Needless to say, there’s a demand for new treatments that can be easily joined with other drugs into a single pill that can be taken once daily and that has minimal side effects.

"One candidate with the potential to meet all of those challenges in S/GSK-572. It is a second-generation integrase inhibitor that can be taken once daily, without the need for blood-level boosting by Norvir (ritonavir), and that so far appears to have minimal side effects. What’s more, the daily dose is small enough that it should be easily combinable with other drugs into a single pill."